Nordic Nanovector ASA (OSE:NANO) announces that an abstract describing
preclinical research with Betalutin® (177Lu-HH1) conducted by the
Company and its scientific collaborators has been accepted for poster
presentation at the 57th Annual American Society of Hematology (ASH)
meeting (5-8 December 2015 in Orlando, FL, USA).
The ASH annual meeting is the premier event for scientific exchange in
the field of hematology, attracting more than 20,000 attendees from all
over the world. Typically, more than 5,000 scientific abstracts are
submitted each year, and more than 3,000 abstracts are accepted for oral
and poster presentations through an extensive peer review process.
Nordic Nanovector submitted two abstracts for presentation at this
year’s meeting, one of which has been accepted as noted above and below.
The second abstract, describing efficacy and safety results of a Phase 1
study with Betalutin® in patients with relapsed CD37+ Non-Hodgkin
Lymphoma, was not accepted for presentation. This abstract was submitted
in August and contains no new material information compared with the
latest poster presented at the 13th International Conference on
Malignant Lymphoma in Lugano, Switzerland in June. The abstract will be
published online in the 3 December 2015 supplemental volume of Blood.
The Company is planning to present updated clinical data from the
ongoing Phase 1/2 dose-finding study at another scientific conference in
early 2016.
The accepted abstract is entitled “Treatment with 177Lu-HH1 Increases
CD20 Expression in Non-Hodgkin Lymphoma Cells in Vitro and In Vivo.”
Details of the poster presentation are as follows:
Authors: Ada H.V. Repetto-Llamazares et al
Abstract No. 3245
Session Name: 802. Chemical Biology and Experimental Therapeutics:
Poster II
Date: Sunday, 6 December 2015
Time: 6:00 PM - 8:00 PM (Eastern Standard Time)
Location: Orange County Convention Center, Hall A
Link to abstract: https://ash.confex.com/ash/2015/webprogram/Paper77654.html
###
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company’s lead clinical-stage product opportunity is
Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates
(ARC) designed to improve upon and complement current options for the
treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with
substantial unmet medical need and orphan drug opportunities,
representing a growing market worth over $12 billion by 2018. Betalutin®
comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low
intensity radionuclide (lutetium-177). The preliminary data has shown
promising efficacy and safety profile in an ongoing Phase 1/2 study in a
difficult-to-treat NHL patient population. The Company is aiming at
developing Betalutin® for the treatment of major types of NHL with first
regulatory submission anticipated in 1H 2019. Nordic Nanovector intends
to retain marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets, while exploring
potential distribution agreements in selected geographies. The Company
is committed to developing its ARC pipeline to treat multiple selected
cancer indications. Further information about the Company can be found
at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20151105006198/en/
Copyright Business Wire 2015